A week after announcing plans to cut 600 jobs in France over three years (or 2% of the workforce in France), as part of a larger plan of saving (1 5 billion), Sanofi publishes this Tuesday morning an annual net profit of 7.37 billion euros, up 7.7%. This increase, in line with expectations essentially analysts due to a favorable foreign exchange impact, because at constant exchange rates, it is displayed down 0.9%.
Meanwhile, turnover in 2015, although a little worse than expected, spring 37 billion euros, up 9.7% but only 2.2% at constant exchange rates.
in 2016, the group expects earnings per share “broadly stable” at constant exchange rates, “unless unfavorable major events unexpected “. In 2015, it was stable at constant exchange rates, as expected, to 5.64 euros, up 8.5% at current exchange rate.
earnings per share will increase only from 2018
But in the coming months, the pharmaceutical company will have to find new growth bases, after a year in which sales of its flagship drug Lantus (diabetes) and oncology, has disappointed. In this area, the fourth quarter figures speak for themselves: over the last three months of 2015, sales in diabetes fell by 12.6% and in oncology 7.9 %.
it was only after his plan to reduce costs by 1.5 billion euros over three years announced in late 2015, it is ie from 2018 Sanofi believes that earnings per share will begin to grow faster than sales
.
No comments:
Post a Comment